Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
LA JOLLA, Calif., May 30, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.
- Jefferies 2017 Global Healthcare Conference, New York, June 6, 2017 at 2:00 p.m. EDT (11:00 a.m. PDT), company presentation and overview
- JMP Securities Life Sciences Conference, New York, June 20, 2017 at 2:00 p.m. EDT (11:00 a.m. PDT), Small Molecule Oncology Drugs: Challenges and Opportunities panel participant
A live audio webcast and replay of the presentation at the Jefferies conference will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
